Joey Chau

Joey has advised on a number of significant M&A transactions, including the following:

2025

• PAG (as the offeror) on its proposed privatization of Shandong Fengxiang (HKSE: 9977) by way of merger by absorption
• Skyworth Group (HKSE: 00751) on its HK$1,088.5 million share buyback by way of general offer
• UBS AG, as the financial adviser to Guotai Junan, on the merger with Haitong Securities. This transaction was named “Deals of the Year 2024” by China Business Law Journal
• MRI (as the offeror) on its proposed take private of Anacle Systems (HKSE: 8353)

2024

• The offeror on its proposed privatization of Vesync (HKSE: 2148)
• A consortium of investors led by Starwood Capital Group, Sixth Street and SSW Partners, and which also includes QIA, Warburg Pincus, and the Founders of ESR Group (ESR), on their proposal to privatize ESR by way of scheme of arrangement from the Hong Kong Stock Exchange
• Oaktree Capital on its cornerstone investment in the listing of S.F. Holding (HKSE: 6936) on the Hong Kong Stock Exchange
• CITIC Capital on its HK$1.46 billion sale of a 20.32% stake in AsiaInfo Technologies Limited (HKSE: 1675) to AsiaInfo Security Technologies Co., Limited (688225.SH)
• Oaktree Capital on its cornerstone investment in the listing of China Resources Beverage (HKSE: 2460) on the Hong Kong Stock Exchange
• Edding Group on its reverse takeover with Genor Biopharma (HKSE: 6998). This transaction was named “Deals of the Year 2024” by China Business Law Journal
• PCCW (HKSE: 0008) on its HK$280 million PIPE investment in the de-SPAC merger of HK Acquisition Corporation (HKSE: 7841) and Synagistics Pte. Ltd.
• Morgan Stanley, as the financial adviser to An Ke Technology and China Ping An Insurance, on the mandatory unconditional cash offers for Lufax Holding (HKSE: 6623; NYSE: LU)
• CICC, as financial adviser, on:
  
  • Shanghai Fosun New Medicine’s privatization of Shanghai Henlius Biotech (HKSE: 2696)
  • Liaoning Financial’s privatization of Bank of Jinzhou (HKSE: 416)
• J.P. Morgan, as financial adviser to L’Occitane Groupe S.A., on its privatization of L’Occitane International S.A. (HKSE: 973). This transaction was named “Most Innovative Deal – APAC & Hong Kong SAR” by FinanceAsia Achievement Awards 2024 and “Deals of the Year 2024” by China Business Law Journal and “M&A Deal of the Year 2024” by IFLR
• GL Capital (as the offeror) on its privatization of SciClone Pharmaceuticals (HKSE: 6600)
• Independent Board Committee of Vinda International Holdings (HKSE: 3331) on the voluntary conditional cash offer from Isola Castle Ltd. This transaction was named “Best M&A Deal - Hong Kong SAR” by FinanceAsia Achievement Awards 2024 and “Deals of the Year 2024” by China Business Law Journal
• CIMC Vehicles (HKSE: 1839) (as the offeror) on its privatization

2023

• ZG Group on its business combination with Aquila Acquisition Corporation
• MoneyHero Group on its business combination with Bridgetown (NASDAQ: BTWN)
• CICC, as financial adviser to Inner Mongolia Yitai Coal (HKSE: 3948; SHSE: 900948), on its privatization
• NetDragon (HKSE: 777) on the spin-off of its core overseas education business through its subsidiary, and the merger of its subsidiary with Gravitas Education Holdings, Inc. (NYSE: GEHI)
• Wynn Macau (HKSE: 1128) on its issuance of US$600 million of convertible bonds
• Power Heritage Group (as the offeror) on its privatization of Jiangnan Group (HKSE: 1366)
• Bain Capital on its minority investment in EcoCeres, a subsidiary of The Hong Kong and China Gas Company Limited (Towngas) (HKSE: 0003)
• SciClone Pharmaceuticals (HKSE: 6600) on its HK$780 million share buyback by way of general offer

2022

• Link REIT (HKSE: 823) on its S$2.16 billion acquisition of a portfolio of assets in Singapore
• Skyworth Group (HKSE: 00751) on its HK$380 million share buyback by way of general offer
• Oaktree Capital on its cornerstone investment in China Tourism Group Duty Free Corporation’s listing on the Hong Kong Stock Exchange
• CICC, as financial adviser, on:
  
  • Shenzhen EVOC Intelligence Technology’s privatization of EVOC Intelligent Technology (HKSE: 2308)
  • Luxshare Precision’s takeover of Time Interconnect Technology (HKSE: 1729)
  • Beijing Chunhui’s privatization of Guodian Technology & Environment Group (HKSE: 1296)
• Oaktree Capital on its cornerstone investment in Thai Life Insurance’s THB37.1 billion (approximately US$1 billion) listing on the Stock Exchange of Thailand
• COFCO Beverages, a subsidiary of COFCO Corporation and China Foods Limited (HKSE: 506), in the acquisition of all of the equity interests in certain wholly-owned subsidiaries of Coca Cola Bottlers Manufacturing Holdings, a joint venture ultimately owned by The Coca-Cola Company, Swire Pacific Limited (HKSE: 00019 and HKSE: 00087) and COFCO Beverages
• Hypebeast (HKSE: 00150) on its proposed listing on NASDAQ through a business combination with Iron Spark (NASDAQ: ISAA)
• Sequoia China Infrastructure Fund on its investment in GDS Holdings (NASDAQ: GDS; HKSE: 9698)

2021

• A consortium of investors, comprising Centurium Capital, PW Medtech Group Limited (HKSE: 1358), CITIC Capital, Hillhouse Capital, Temasek and Marc Chan, on the US$4.6 billion take-private of China Biologic Products (NASDAQ: CBPO)
• CICC, as financial adviser, on:
  
  • Yunan Baiyao’s takeover of Ban Loong Holdings (HKSE: 30)
  • The take-private of Suchuang Gas (HKSE: 1430) by China Resources Gas
  • China Modern Dairy (HKSE: 1117)’s acquisition of Inner Mongolia Fuyuan International
• UBS AG, as financial adviser to CPF Investment Limited, on its privatization of C.P. Pokphand (HKSE: 43)
• Artisan Acquisition Corp. (NASDAQ: ARTAU) on its business combination with Prenetics Group
• Carlyle on its US$210 million investment in HUTCHMED
• JD Property (as the offeror) on its US$2 billion take-private of China Logistics Property Holdings (HKSE: 1589)
• Oaktree Capital on its US$100 million cornerstone investment in JD Logistics’ listing on the Hong Kong Stock Exchange
• CMGE Technology Group (HKSE: 302) on its US$100 million issue of new shares to Bilibili Inc. (NASDAQ: BILI)
• J.P. Morgan, as financial adviser to Country Garden Services (HKSE: 6098), on its privatization of Sichuan Languang Justbon Services Group (HKSE: 2606)
• Ocean Link Partners and Sequoia Capital China (as the consortium offeror) on the take-private of Zhejiang New Century Hotel Management

2020

• CICC, as financial adviser, on:
  
  • Luxvisions Innovation Technology Limited’s takeover of Cowell (HKSE: 1415)
  • Shandong Gold Mining (HKSE: 1787)’s take-private of Hengxing Gold Holding (HKSE: 2303)
  • SanXing Trade’s privatization of Changshouhua Food Company (HKSE: 1006)
• Car Inc. (HKSE: 699) on its take-private by MBK Partners and its issue of US$175 million of convertible bonds to MBK Partners Special Situations fund
• Loyal Valley Capital, as a member of an investor consortium, on the privatization of O-Net Technologies (HKSE:877)
• Advantage Partners on its primary and secondary general partner share sale to, and strategic partnership with, Tokyo Century Corporation
• Li & Fung on US$100 million strategic investment by JD.com
• Huatai Financial Holdings, as financial adviser, on the privatization of Huarong Investment Stock Corporation Limited (HKSE: 2277)
• Skyworth Group (HKSE: 00751) on its HK$1.1 billion share buyback by way of general offer
• Lilly Asia Ventures on its cornerstone investment in Peijia Medical Limited
• GLP and the consortium offeror comprising the Fung family and GLP, on its privatization of Li & Fung (HKSE: 494)

2019

• TPV Technology (HKSE: 903, SGX: T18) on its privatization by China Electronics Corporation
• Nan Fung Group on its US$110 million acquisition of a minority stake in Hong Kong International Construction Investment Management Group (HKSE: 687)
• Blackstone on its US$400 million subscription of H shares convertible bonds in Hong Kong-listed YiChang HEC ChangJiang Pharmaceutical (HKSE: 1558)

2018

• Loyal Valley Capital and TR Capital on their cornerstone investments in the US$414 million listing of Shanghai Junshi Biosciences on the Hong Kong Stock Exchange

• UBS AG, as financial adviser, on the US$671 million unsolicited conditional voluntary general offer of Spring REIT by PAG Real Estate

• Malaysian sovereign fund on its investment in the US$14 billion Series C equity financing of Ant Financial

2017

• Bank of America Merrill Lynch, as financial adviser, on the $6.8 billion privatization of Belle International

• MicroPort Scientific Corporation (HKSE: 853) on its US$190 million acquisition of the Cardiac Rhythm Management business of LivaNova PLC

• Midea (as the offeror) on its privatization of Welling

• Ally Bridge Group (as a joint offeror) on its US$300 million privatization of Shandong Luoxin Pharmaceutical Group (HKSE: 8058)

• The Carlyle Group, CITIC Limited and CITIC Capital Holdings on the US$2.08 billion acquisition of the McDonald’s operations in China and Hong Kong

2016

• COFCO Coca-Cola Beverages, a subsidiary of China Foods Limited (HKSE: 506) and a subsidiary of state-owned COFCO Corporation, on its acquisition of the bottling operations from The Coca-Cola Company and Swire Beverages

• J.P. Morgan, as financial adviser, on CVC Capital Partners-led funds’ US$1.1 billion privatization of Nirvana Asia (HKSE: 1438)

• Ascendent Capital Partners on the takeover of China Automation Group (HKSE: 569)

• Malaysian sovereign fund on its investment in Cainiao and WeLab

2015

• China Grand Automotive Services (SSE: 600297) (as the offeror) on its US$1.5 billion partial offer for Baoxin Auto Group (HKSE: 1293)

• Vipshop (NYSE: VIPS) on its €30 million investment in the IPO of Showroomprive.com (IPO-SHOW.PA) on Euronext Paris

• China Traditional Chinese Medicine (HKSE: 570) on its HK$8.2 billion equity placing and its US$1.43 billion acquisition of Jiangyin Tianjiang Pharmaceutical

• Pokka Corporation (Singapore) on its sale of Pokka Corporation (HK) and Pokka Coffee (Macau) to Xiao Nan Guo Restaurants (HKSE: 3666)

2014

• Shanghai Pudong Science and Technology Investment on its US$693 million acquisition of NASDAQ-listed Montage Technology Group

• CCB International on its purchase of secured notes and warrants issued by China Gui Tea

• 21st Century Fox on its sale of a 49.9% stake in Star China TV to China Media Capital

2012–2013

• Beijing Wangfujing (as the offeror) on its take-private of PCD Stores

• NCGA Holdings on its US$305 million acquisition by Baoxin Auto Group (HKSE: 1293)

• CITIC Securities (HKSE: 6030) on its US$1.252 billion purchase of CLSA

2011–2012

• TPV Technology (HKSE: 903) on its acquisition of a 70% interest in a joint venture company which owns and controls the entire television business of Philips

Skadden, Arps, Slate, Meagher & Flom (Hong Kong)